AstraZeneca was exposed to divest heavy breathing products, set up a new company to take over
Recently, industry sources said that AstraZeneca will form a new company with a "Chinese" investment company, and AstraZeneca will transfer its respiratory product line to this new company, and complete the staff signing before July 1.
According to analysts, AstraZeneca spun off the new company mainly because of the impact of pooling. Due to the contraction of profits, the related products will gradually become the company's non-core assets, and the newly established company mainly manages some of the collected product lines divested by the company, and more collected products are expected to be transferred in the future, such as the digestion product line.
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
β-Nicotinamide Adenine Dinucleotide High Quality NAD+ CAS 53-84-9 Exclusive Production Factory CAS NO.53-84-9
$75/UNIT FOB
2026-07-17
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Germany Passes Healthcare Reform, Multinational Drugmakers Face 15.5% Mandatory Discount
-
AstraZeneca’s Wainua Fails Phase III Heart Trial, Wiping Out About $27 Billion in Market Value
-
$15 Billion Invested in China: AstraZeneca Builds an “Innovation Hub” While Some Are Still Waiting for the Windfall
-
AstraZeneca to Invest $2 Billion in New U.S. Biologics Facilities
-
The relationship between Digital Transformation and Work- Life Balance in the Egyptian Pharmaceutical Industry
-
AstraZeneca to Invest $2.5 Billion to Establish Global Drug R&D Center in Beijing
-
AstraZeneca to invest $3.5 billion in the United States
-
Ascending to the Summit: AstraZeneca Crowned as the Most Competitive MNC in China
-
Restructuring at AstraZeneca China: Leadership Changes and New Business Division
-
What Does the Future Hold for the Anti-Obesity Drug Market in 2024?
Recommend Reading
-
Merck to Lay Off 150 Workers at US Gardasil Plant Amid Sales Weakness
-
MENA Pharmaceutical Regulatory Updates 2026: Key Compliance Changes for Global Pharma Companies
-
Alipay, Baidu, and iFlytek Win Big—As the Government Spends $1.1 Billion on AI Healthcare, Is This a Lifeline or a Feeding Frenzy for Tech Giants?
-
Sun Pharma’s Winning Formula: Precision Over Expansion
-
The Oral GLP-1 Cage Match: Orforglipron vs Rybelsus
-
China Extends Anti-Dumping Duties on Phenol Imports from US, EU, Korea, Japan, Thailand
-
Costs Rise, Hydrogen Peroxide Market Prices See an Increase
-
“Shutdown Equals Price Hike”: TDI Market Enters a New Era of “Scarcity Games”
-
Yangfan New Material’s Controller Under Investigation by Authorities
-
This week, the mainstream price of propylene oxide in the Chinese market has exceeded the 10,000 yuan mark (3.9-3.10)